Dr. Kornblau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1400 Holcombe Blvd
Unit 428
Houston, TX 77030Phone+1 713-792-8760Fax+1 713-794-1938
Education & Training
- Royal Free Hospital,MD, Benign hematology, 1991 - 1991
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
- Baylor College of MedicineResidency, Internal Medicine, 1985 - 1988
- University of Texas Medical Branch School of MedicineClass of 1985
Certifications & Licensure
- FL State Medical License 2021 - Present
- GA State Medical License 2023 - 2026
- OK State Medical License 2023 - 2026
- WA State Medical License 2023 - 2026
- AZ State Medical License 2023 - 2025
- LA State Medical License 2023 - 2025
- MS State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- Join now to see all
Publications & Presentations
PubMed
- Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
Cancer. 2024-11-25 - Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.Satoshi Yoshimura, Zhenhua Li, Yoshihiro Gocho, Wenjian Yang, Kristine R Crews
Journal of Clinical Oncology. 2024-10-10 - Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk.Shunsuke Kimura, Chun Shik Park, Lindsey E Montefiori, Ilaria Iacobucci, Petri Pölönen
Cancer Discovery. 2024-10-04
Journal Articles
- Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular SubtypesKoichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
- Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular SubtypesKoichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
- Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic LeukaemiaMichael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
Abstracts/Posters
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaSteven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Proteomic Landscape of Acute Leukemia: A Comparison between ALL and AML in AdultsSteven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
Press Mentions
- Myelodysplastic Syndrome Survivor: A Stem Cell Transplant Put Me in RemissionSeptember 3rd, 2019
- New TMC Program Will Streamline Clinical TrialsJune 3rd, 2019
Grant Support
- Core B - Myeloma Tissue CoreNational Cancer Institute2010–2011
- CML Cell BankNational Cancer Institute2010–2011
- Pathology And Tissue CoreNational Cancer Institute2008–2011
- Sample Distribution, Processing And Culture CoreNational Cancer Institute2007–2011
- High Throughput Transcriptomics And ProteomicsNational Cancer Institute2007–2011
- Sample Distribution, Processing, Banking And DatabaseNational Cancer Institute2005–2009
- Core--Sample Distribution, Processing And CultureNational Cancer Institute2001–2002
- Suicidal Lymphocytes For Induction Of Gvl--CmlNational Cancer Institute1998–2002
- Core--Cell Collection, Fractionation, Growth, And Transplantation LaboratoryNational Cancer Institute1996–2001
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: